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1. Introduction
Biosimilars of infliximab were first approved by the European 
Medicine Agency in 2013,1,2 based on pre-clinical studies on 
biosimilarity and on clinical data coming from two randomised 
controlled trials conducted in rheumatoid arthritis [RA] and anky-
losing spondylitis [AS].3,4 Initially the European Crohn’s Colitis 
Organisation [ECCO] raised some caution on the use of bio-
similars.5 This cautious approach was also supported by several 
national inflammatory bowel disease [IBD] societies5–12 [Table 1]. 
An insufficient understanding of the characteristics and use of bio-
similars became evident in a web survey among ECCO members in 
the same period.13
Since biosimilars were introduced in the EU market in early 
2015, more data from IBD patients14–19 have supported the biosimi-
larity of biosimilar infliximab CT-P13 and the reference product, 
with no significant differences in terms of efficacy or safety, in either 
naïve or switched patients in cohort studies. Importantly, a study 
showed clear cross-reactivity between the infliximab originator and 
CT-P13.20 Recently, a large nationwide Norwegian randomised con-
trolled trial [NOR-SWITCH] on patients with immune-mediated 
diseases [Crohn’s disease; ulcerative colitis; psoriasis; psoriatic 
arthritis; RA and AS] found no differences in terms of clinical 
response, maintenance of remission, or adverse events in patients 
receiving CT-P13 compared with those receiving originator inf-
liximab.21 Consideration of these findings22 together with a better 
understanding of the process of biosimilar development and regula-
tory approval, have contributed to a change in the perception of 
IBD experts, who now prescribe biosimilars with significantly more 
confidence.23
A task-force including Governing Board representatives and one 
representative from pertinent ECCO Committees performed a litera-
ture search and made relevant statements to summarise their shared 
position. The proposed statements were then discussed, agreed and 
approved in a Consensus meeting.
2. Regulatory Process by EMA for Biosimilars
The licensing of any biosimilar medication by the European 
Medicines Agency [EMA] is subject to strict regulatory oversight. 
Many of the principles are shared with the regulatory processes 
governing the licensing of generic chemical compounds, but due 
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a series of directives have been applied specifically to biosimilars. 
Taken together, these require a body of evidence of biochemical and 
clinical equivalence to the originator compound, as well as assurance 
of the quality and oversight of production.24
At the biochemical level, the compounds must first demon-
strate equivalent composition. The primary structure is analysed 
[e.g. amino acid composition analysis, peptide mapping, C- and 
N- terminus sequencing] with particular attention to analysis of 
post-translational modifications, which are liable to variation due 
to differences in cell lines used for antibody expression. The higher 
order structure of the biosimilar is also determined [e.g. disulphide 
bond mapping], and impurity analysis performed. Next, the biosimi-
lar must be characterised in vitro against the originator compound 
to demonstrate biological characteristics relevant to the mechanism 
of action of the drug. For anti-tumour necrosis factor [TNF]-α bio-
similars, this includes demonstration of neutralisation of TNF-α, as 
well as the induction of apoptosis, the ability to fix complement and 
drive antibody-dependent cell-medicated cytotoxicity in a range of 
cells, and tests of the binding affinities of the constant [Fc] region 
of the antibody to cellular receptors. Further physicochemical tests 
include measures of batch-to-batch consistency, as well as verifica-
tion of stability data. Full oversight of the manufacturing process 
takes account of procedures for buffer manufacture and storage, fil-
tration and lyophilisation procedures, and all aspects of packaging. 
Given the large number of biological materials used in manufacture, 
the EMA also scrutinise risk management for prevention of trans-
mission of infectious agents, including prions, mycoplasma, and viral 
agents.25–27
Clinical data must then be presented to demonstrate: [i] phar-
macokinetic and pharmacodynamic equivalence to the originator 
compound, including immunogenicity data; and [ii] clinical efficacy 
equivalence in one of the licensed indications. Multiple data analyses 
are scrutinised by the EMA, with pivotal examples set out in Table 2. 
Where the mechanism of action of the drug is well established and 
common between multiple indications, clinical data from equiva-
lence studies in one reference disease indication form the basis for 
extrapolation of the efficacy and safety data to other licensed indica-
tions without the need for specific clinical trials in these other indi-
cations [see extrapolation below]. However, where the action is less 
well characterised, where patient populations may differ in risk, or 
where the mechanism of action may differ between indications, more 
extensive pre-clinical data will be required to support licensing.28
An important consideration is that EMA experts assess evidence 
in a dynamic manner, with the opportunity to seek further data from 
the applicant at any stage. For example, during the assessment of 
post-translational modification for CT-P3 [the biosimilar inflixi-
mab CT-P13 approved and marketed as Remsima and Inflectra] it 
became clear that there were differences in Fc region fucosylation 
that impacted upon binding to the Fc receptor FcγRIII. A series of 
further in vitro assays were performed to assess the functional sig-
nificance of this, demonstrating differences in binding affinities to 
natural killer [NK] cells but not neutrophils. The applicant was able 
to demonstrate that these differences in NK cell binding were not 
observed in the presence of diluted serum from a Crohn’s disease 
patient, and in dialogue with the EMA was successful in arguing that 
any FcγRIII binding differences were not of clinical significance.1,2
3. Extrapolation
The concept of ‘extrapolation of indications’ [or, to use the offi-
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evidence’] has been much discussed since the first general guidelines 
were developed by the Committee for Human Medicinal Products 
[CHMP] in 2005.25,26 The aim was to cover cases where the origi-
nally authorised biological medicinal product [the so-called ‘refer-
ence medicinal product’] had been authorised for several indications 
and to determine whether or not the medicinal product claiming to 
be similar could also be authorised for the same set of indications. 
To answer this question, the initial concept was that the efficacy and 
safety profile ‘has to be justified or, if necessary, demonstrated sepa-
rately for each of the claimed indications. In certain cases, it may be 
possible to extrapolate therapeutic similarity shown in one indica-
tion to other indications of the reference medicinal product…’ This 
notion of extrapolation was essentially based on ‘appropriate justifi-
cations’,29 including consideration of the clinical experience and the 
mechanism of action and whether the ‘same receptor’ is involved.26
Later updates of the EMA guidelines have used more specific word-
ing, and the notion has evolved gradually, depending on the product 
concerned. The first evolution was that if the indication used to demon-
strate clinical comparability was the ‘most sensitive and relevant’, the 
extrapolation of the results to the other indications would be possible, 
providing the mechanism of action is the same.26,29–31 However, unlike 
biosimilars of simple molecules, marketing authorisation for complex 
molecules, such as monoclonal antibodies [mAb] is very complex. 
Thus, for biosimilars of mAb, we have witnessed a progressive evolu-
tion in reasoning and approach, first announced by Schneider et al.31 
and further confirmed in the most recent published EMA guideline,32 
which states that ‘Extrapolation of clinical efficacy and safety data to 
other indications of the reference mAb, not specifically studied during 
the clinical development of the biosimilar mAb, is possible based on 
the overall evidence of comparability provided from the comparability 
exercise and with adequate justification’ but not as an ‘automatic or 
systemic conclusion’.27,33–35 In this regard, the EMA has incorporated 
the mode of action of monoclonal antibody biosimilars in the ‘totality 
of evidence with adequate and relevant justification’.35
Despite a stringent approval process, acceptance of biosimilars in 
the medical community encountered some resistance. This appears 
to be especially true for therapeutic indications for which no specific 
clinical trials with the biosimilar have been performed and that have 
been approved based on extrapolation. Reasons for this distrust may 
be several, including the cited paradigm that biosimilars are ‘similar 
but not identical’, and the fact that clinicians tend to mainly look 
at clinical trial data for their own disease area to judge the efficacy 
and safety of a medicinal product. However, biosimilar develop-
ment programmes are not aimed at demonstrating clinical efficacy 
of biosimilars in a particular clinical condition, since this has already 
been established for the reference product, but to demonstrate simi-
larity with the reference product in highly sensitive experimental 
conditions using state-of-the-art analytical tools.28 Thus, regulatory 
requirements for the development of a biosimilar demand a compre-
hensive comparability exercise, as detailed above.25,26,36 The rigour 
of this exercise is such that biosimilarity can usually be character-
ised much more sensitively by performing appropriate assays than 
clinical studies.35 Demonstration of clinical equivalence must then be 
achieved in a study population where the sensitivity to the treatment 
effect is maximised, that is a clinical indication where original trial 
data suggested the smallest difference from placebo, even at the cost 
of not representing the real target population. However, the resulting 
data should be relevant to the target indication.26,33,36 This paradigm 
may seem counterintuitive to practitioners, and some of them may 
be reluctant to use a biosimilar in an indication for which therapeu-
tic equivalence has not been specifically tested. In that regard it is 
important to consider that two biological products showing similar-
ity across a comprehensive non-clinical and clinical data package 
will behave similarly in an insensitive therapeutic clinical study aim-
ing to show therapeutic equivalence. This line of thinking is the cor-
nerstone behind the revision of the biosimilar regulatory approach.37
The EMA granted a positive opinion for the first biosimilar 
monoclonal antibody CT-P13, a biosimilar of Remicade, in 2013.1 
This was based on the notion of ‘totality of evidence’, meaning the 
inclusion of robust comparisons of the physicochemical and in vitro 
and ex vivo biological analyses, dose-dependent suppression of pro-
inflammatory cytokines, and inhibition of apoptosis demonstrated 
in a model of inflammation, among other extensive tests. It is clearly 
indicated in the public assessment report that the applicant has 
covered the two recommended doses of infliximab [3 and 5 mg/kg; 
Remicade] and that additional pharmacokinetics, pharmacodynam-
ics, and potency test results have been considered in the ‘totality of 
evidence’ approach. The same principles guided the approval of the 
second Remicade biosimilar, Flixabi, in 2016.38
The principle of extrapolation should consider both the patient 
perspective and the cost of development. From the patient perspec-
tive, it is the duty of the competent authorities to authorise a copy 
version of a reference medicinal product with the guarantee that it 
will exhibit the same efficacy and safety, whatever the development 
plan adopted. From the economic perspective, it is also a duty not to 
impose unnecessary repetition of tests and waste resources to con-
firm what can be established by appropriate analytical and func-
tional tests and justifications. The ‘totality of evidence’ is certainly a 
Table 2. Summary of pivotal clinical data required for EMA application for biosimilarity and examples for biosimilar infliximab.
Characteristic Requirements CT-P1325,26 [Inflectra, Remsima] SB229 [Flixabi]
PK assessment Multiple parameters tested in rodent and 
human studies. eg: 90% CI for AUC and 
Cmax must be within 90–125% of  
originator
Phase I PK study versus Remicade in  
ankylosing spondylitis patients [n = 250]: 
AUC: 104% [94–115%], Cmax: 101% 
[95–109%]
Phase I PK study versus Remicade 
in healthy subjects [n = 106]: AUC: 
99% [90–108%], Cmax: 101% 
[96–105%]
Efficacy assessment Evidence of efficacy equivalent to that of 
originator compound in phase III study 
for one of licensed indications, eg 95% CI 
for primary endpoint must be < ± 15% of 
originator
54-week phase III study in rheumatoid 
arthritis patients on methotrexate [n = 606]. 
Primary endpoint [% ACR20 responders at 
Week 30] 60.9% [CT-P13] vs 58.6%  
[Remicade]. [95%CI for difference: -6%  
to +10%]
54-week phase III study in  
rheumatoid arthritis patients on 
methotrexate [n = 584].Primary 
endpoint [% of ACR20 responders 
at Wee k30] 64.1% [SB2] versus 
66.0% [Remicade]. [95% CI for 
difference: -10.3% to +6.5%]
EMA, European Medicines Agency; AUC: area under concentration/time curve after administration of test dose; Cmax: peak concentration; CI: confidence 
interval; PK: pharmacokinetic; ACR20: American College of Rheumatology scoring system 20% response.
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scientific and pragmatic approach; ‘extrapolation of indication’ can-
not be an automatic or systematic conclusion.
When a biosimilar product is registered in the EU, it is considered 
to be as safe and efficacious as the reference product when used in 
accordance with the information provided in the summary of prod-
uct characteristics. However, the two trials required by the EMA to 
approve a biosimilar mAb may not be sufficient to detect differences 
in the safety profile related to very infrequent events. In contrast 
to post-marketing monitoring of the safety for generic medicines, 
post-marketing safety monitoring of biosimilars is a formal regula-
tory requirement in the EU. This requirement is as stringent as for 
any other biological product, and requires the provision and evalu-
ation of a risk management plan and for there to be an adequate 
pharmacovigilance system in place. This is aimed not only to track 
and monitor potential differences in the immunogenicity profile, but 
also to be a proactive system to minimise and detect identified and 
potential risks associated with the product, even if they are rare. 
The initial observational data published on efficacy and safety of 
CT-P13 in IBD,19 including immunogenicity data20,39 show a profile 
that completely overlaps with the originator.
4. Interchangeability and Switching
To further assess data relating to the efficacy of biosimilars drugs in 
IBD, we performed an update of a recent systematic review.40 A total 
of 15 studies met the inclusion criteria for reporting efficacy, safety, 
and immunogenicity [Tables 3–5].
The first reports on switching from the originator to biosimi-
lar infliximab in IBD demonstrated similar clinical efficacy of the 
biosimilar infliximab compared with the originator compound.40–43 
Several cohort studies across Europe have evaluated clinical efficacy, 
safety, and immunogenicity in patients who were switched from the 
originator to CT-P13.14–18,44–48 Over a total of 497 patients switched 
from originator to CT-P13 in different countries [Spain, the UK, 
Table 3. Characteristics of the studies evaluating the efficacy of CT-P13 in IBD patients.40




[32 anti-TNF naïve CD, 42 anti-TNF 
naïve UC]
CD: 90.6% at Week 8, 95.5% at Week 30, 
87.5% at Week 54
UC: 81% at Week 8, 91.3% at Week 30, 
100% at Week 54
CD: 84.4% at Week 8, 77.3% at Week 30, 
75% at Week 54
UC: 38.1% at Week 8, 47.8% at Week 30, 





[83 moderate-to-severe CD, 12  
fistulizing CD or 78 moderate-to-severe 
UC]
Moderate-to-severe CD: 87.2% at Week 14, 
79.5% at Week 30
Fistulising CD: 66.7% at Week 14, 66.7% 
at Week 30
Moderate-to-severe UC: 75.5% at Week 14, 
- 72.2% at Week 30
Moderate-to-severe CD: 69.2% at  
Week 14, 59% at Week 30
Fistulising CD:
33.3% at Week 14, 50% at Week 30
Moderate-to-severe UC: 49.1% at  
Week 14, 37% at Week 30
Kang YS et al.,
South Korea41
17 patients enrolled [8 CD, 9 UC]. 
Induction treatments were done in 5 UC 
and 3 CD patients




39 patients enrolled [18 CD, 21 UC]. 
Induction treatment was completed in 
16 CD patients and 15 UC patients
CD: 37.5% at Week 8
UC: 20% at Week 8
CD: 50% at Week 8
UC: 66.7% at Week 8
Farkas et al.,
Hungary45
63 UC patients [24 in acute severe flare- 
up, 39 in chronic, refractory activity]




210 patients [126 CD, 84 UC] CD: 81.4% at Week 14
UC: 77.6% at Week 14
CD: 53.6% at Week 14
UC: 58.6% at Week 14
Gecse K et al.,
Hungary68
291 patients [184 CD, 107 UC] CD: 83% at Week 14, 77% at Week 30, 
58% at Week 54
UC: 78% at Week 14, 69% at Week 30, 
64% at Week 54
CD: 55% at Week 14, 57% at Week 30, 
47% at Week 54
UC: 59% at Week 14, 46% at Week 30, 
53% at Week 54
Keil R et al.,
Czech Republic69
52 patients [30 CD, 22 UC] Partial response in CD [≥ 70-point decrease 
in CDAI score from baseline] at Week 14: 
50%
Partial response in UC [≥ 2-point decrease in 
partial Mayo score from baseline] at Week 
14: 54.5%
Remission in CD [CDAI < 150] at Week 
14: 50% remission in UC [total score on 




78 patients [46 CD, 32 UC] N.A. CD: 79% at Week 14
UC: 56% at Week 14
Smits LJ et al.,
The Netherlands70





104 patients [79 CD, 25 UC] CD: 89.6% at Week 22
UC: 78.3% at Week 22
UC: 50% of mucosal healing [Mayo  
endoscopic sub-score 0 or 1] at Week 22
Kolar M et al.,
Czech Republic47
74 patients [56 CD, 18 UC] After switching from original to biosimilar IFX: disease activity was stable until the 
end of follow-up [remission at Week 0 versus Week 24: 72% versus 78%]. One patient 
presented loss of response
Fiorino G et al.,
Italy15
397 patients [223 CD, 174 UC] Were considered responders: 144/156 naïve 
patients [69 CD]. 49/58 previously exposed 
to anti-TNF [42 CD] and 77/82 [43 CD] 
switched
N.A.
CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; TNF, tumour necrosis factor; IFX, infliximab; CRP, C-reactive protein; N.A., not 
available; CDAI. Crohn’s Disease Activity Index.
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The Netherlands, and the Czech Republic], treatment persistency 
ranged from 57% to 88% at the end of the follow-up. No significant 
increase in terms of adverse events was found in any of those stud-
ies. Positivity to anti-drug antibodies [ADA] was similar between the 
baseline and the end of the follow-up.
Preliminary data from a prospective, nationwide, observational 
cohort by Fiorino et  al., including the largest population of IBD 
patients [n = 547, CD/UC: 312 /235], showed that the response rates 
in patients following the induction regimen or at least two infusions 
with CT-P13 was 90% in anti-TNF naïve patients, 89% in patients 
receiving re-induction after previous treatment with anti-TNF, and 
100% for those stable patients switched to biosimilars from origina-
tor. After a median follow-up of 4 months, the rate of loss of response 
in switched patients was 7.9% compared with 17.8% and 29.1% 
in naïve patients and in patients previously treated with anti-TNF 
[p = 0.08], respectively; 66 [12%] adverse events occurred, mainly 
infusion reactions [58%], leading to discontinuation of biosimilar 
infliximab therapy in 45 patients [8%]. Infusion reactions occurred 
in a significantly higher proportion of patients [incidence rate ratio: 
2.82; 1.05–7.29] previously exposed to infliximab in whom treat-
ment had been stopped for a drug holiday > 4 months.15
Further data on switching from the originator to biosimilar 
infliximab therapy from ongoing trials are about to be published. 
The randomised, phase-IV, double-blind, parallel-group NOR-
SWITCH study49 [NCT02148640] was initiated to test inter-
changeability from originator to biosimilar infliximab in patients 
with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, 
ulcerative colitis [UC], Crohn’s disease [CD], and chronic plaque 
psoriasis.21 It was designed as a non-inferiority trial with a non-
inferiority margin set to 15%. Power calculations indicated that 
394 patients were required in the primary per protocol set [PPS]. 
All adult patients on stable treatment with the originator infliximab 
for at least 6 months for any indication were eligible. Patients with 
informed consent were randomised 1:1 to either continue origina-
tor infliximab or switch to CT-P13 treatment using an unchanged 
dosing regimen. The primary endpoint was disease worsening dur-
ing follow-up according to a worsening in disease-specific compos-
ite measures and/or a consensus between investigator and patient 
Table 4. Characteristics of the studies evaluating the safety of CT-P13 in IBD patients.40
Study Study population Adverse events Infusion-related 
reaction
Death
Jung YS et al., 
South Korea42
74 patients [32 anti-TNF naïve CD, 42  
anti-TNF naïve UC]
N.A. 0 0
Park SH et al., 
South Korea43
173 patients [83 moderate-to-severe CD,  
12 fistulising CD, 78 moderate-to-severe UC]
Mild-moderate in severity: 10%. Infections: 2, 
abdominal pain: 1
2 0
Keil R et al., 
Czech Republic69
52 patients [30 CD, 22 UC] Lower-extremity phlebothrombosis: 1, herpes 
labialis: 1, pneumonia: 1
1 0
Gecse KB et al., 
Hungary16
210 patients [126 CD, 84 UC] 17.1% of all patients, infections: 5.7% 6.6% 0
Gecse KB et al., 
Hungary68
291 patients [184 CD, 107 UC] Infections: 23 [7.9%] 21 [6.6%] 1
Smits LJ et al., 
The Netherlands70
83 patients [57 CD, 24 UC, 2 IBD- 
unclassified]
N.A. N.A. 0
Bortlik M et al., 
Czech Republic71
104 patients [79 anti-TNF naïve CD, 25  
anti-TNF naïve UC]
Infections: 10, skin lesions: 10 0 0
Kolar M et al., 
Czech Republic47
74 patients [56 CD, 18 UC] 1 0 0
Fiorino G et al., 
Italy15
397 patients [223 CD, 174 UC] 33 [8.3%] 21 [5.3%] 0
CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; AEs, adverse events; N.A., not available, TNF, tumour necrosis factor.
Table 5. Characteristics of the studies evaluating the immunogenicity of CT-P13 in IBD patients.40
Study Study population Antidrug antibodies [ADA]
Gecse KB et al., 
Hungary16
210 patients [126 CD, 84 UC] Baseline ADA positivity was detected in a significantly higher 
number of patients who had received previously IFX treatment 
as compared with IFX-naïve patients
Kolar M et al., 
Czech Republic47
74 patients [56 CD, 18 UC] No increase in immunogenicity was found after switching from 
originator to biosimilar IFX
Ben-Horin S et al.20_ Sera from 125 IBD patients and controls All 56 anti-Remicade® ADA-negative control sera were also 
negative for anti-Remsima® ADAAll 69 positive anti- 
Remicade® IBD sera were cross-reactive with Remsima®
Malickova K et al., 
Czech Republic72_
60 IFX-naïve IBD patients treated by the bio-
similar IFX [Remsima®] and 71 IBD patients 
treated by the innovator IFX [Remicade®]
At Week 2: no significant difference in proportion of patients with 
positive ADA was observed between original and  
biosimilar IFXAt Week 14: the proportion of patients with  
positive antibodies [ADA, ANA, anti-dsDNA, and anti-ENA] was 
not different comparing therapy with original and biosimilar IFX
CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; IFX, infliximab; ADA, antidrug antibodies; ANA, antinuclear antibodies; 
anti-dsDNA, anti-double-stranded DNA; anti-ENA: anti-extractable nuclear antigens.
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leading to major change in treatment. This study enrolled 481 
patients, from 40 Norwegian study centres. They were randomised 
to receive treatment and were followed for 52 weeks. Disease wors-
ening occurred in 26.2% and 29.6% of patients in the originator 
and CTP13 arms, respectively (difference -4.4%, 95% confidence 
interval [CI] -12.7–3.9). The frequency of disease worsening in 
each specific diagnosis, and changes in the generic disease varia-
bles and disease-specific composite measures, were not different in 
either of the arms. The incidence of anti-drug antibodies detected 
during the study was 17 [7.1%] and 19 [7.9%] in the originator 
and CT-P13 patients, respectively. Trough drug levels and the fre-
quencies of reported adverse events, including infusion reactions, 
were also not different.21
Furthermore, a randomised, double-blind, parallel-group, phase 
3 study [NCT02096861] is ongoing to demonstrate non-inferiority 
in efficacy and to assess overall safety of CT P13 compared with 
Remicade in patients with active Crohn’s disease.50 The aim of the 
phase 4 SIMILAR trial [NCT02452151] is to assess efficacy of bio-
similar infliximab compared with the originator compound in CD 
and UC patients in remission under treatment with infliximab for 
up to 3 months.50
Limited data are available on paediatric IBD patients. In a multi-
centre observational cohort enrolling 32 paediatric patients, studied 
by Sieczkowska et al., 88% of CD and 57% of patients who were 
switched still maintained clinical remission in the follow-up time 
[median time for CD 8 ± 2.6 months; UC: 5 ± 3.6 months]. Only one 
CD patient had an allergic reaction after switching. ADA and trough 
levels were not different from the baseline.
In conclusion, there have been no reports so far that switching 
from the reference to the biosimilar infliximab CT-P13 has caused 
problems, in either adult or paediatric IBD patients. On the con-
trary, an increasing number of publications have shown that there 
are no safety or efficacy concerns about switching. No studies have 
addressed so far efficacy, safety, and immunogenicity of cross-switch-
ing [switching between two biosimilars], reverse-switching [switch-
ing from a biosimilar to its originator], or multiples or repeated 
switches. However, from an immunological point of view it should 
be noted that antibodies can develop usually within 2–3 treatments; 
therefore to support a high level of pharmacovigilance, a switch 
within 6 months due to non-medical reasons should not be advised.
5. Immunogenicity
Immunogenicity is a well-known complication during treatment 
with biologic agents and involves the formation of anti-drug anti-
bodies [ADAs] affecting treatment. For anti-TNF drugs, ADAs are 
associated with alterations in anti-TNF levels, reduced efficacy, 
and side-effects including allergic reactions. A  systematic review51 
reported on ADA formation in a total of 68 studies of anti-TNF 
treated patients, with a cumulative incidence of ADAs of 12.7%, 
which was highest in patients using infliximab [25.3%].
The best level of evidence outside IBD came from two ran-
domised controlled trials [RCTs] [PLANET-RA and PLANET-AS], 
showing no difference in terms of ADA formation between the study 
populations treated with either infliximab originator and or CT-P13, 
at Weeks 523,4 and 104.52,53 A  recent systematic review54 reported 
no increased ADAs formation in RA patients treated with biosimi-
lars and concluded that immunogenicity seemed comparable across 
treatment groups in in all studies.
In IBD, following the publication of cohort studies [Table 5] 
an interesting study showed high similarity in binding, illustrating 
similar immunogenicity and the presence of shared immune-dom-
inant epitopes in CT-P13 and infliximab originator sequences. 
In addition, anti-adalimumab antibodies did not cross-react 
with CT-P13 or infliximab originator.20 More recently, the 
NORSWITCH study21 clearly established that no differences in 
terms of ADA formation were found between patients switched 
to CT-P13 and all the study patients or the subgroups of patients 
stratified for disease.
Data from the clinical development programme that led to the 
very recent approval of SB2 biosimilar of infliximab [Flixabi] has 
shown a slight excess of ADA positivity which was higher in the 
RA trial.38 ADA rates were higher in the Flixabi cohort by 5–12% 
at the individual time points of determination [with about 50% of 
patients in the Flixabi cohort determined ADA-positive]. Despite 
these numerical differences observed, there was no meaningful effect 
on any of the efficacy parameters analysed. Sub-group analyses did 
not reveal differences of clinical relevance in either ADA-positive 
or ADA-negative subjects when comparing Flixabi and originator 
cohorts. Limitations in the immunogenicity assays that were used 
to test ADA may explain the higher incidence of ADA in the Flixabi 
cohort.38
6. ECCO Statements
A consensus meeting was held on October 15, 2016 in Vienna. Based 
on the current regulatory guidance form the European Medicines 
Agency and the evidence about efficacy and safety of biosimilars in 
IBD patients, the attendees agreed on the following statements:
1. Biosimilarity is more sensitively characterised by performing 
suitable in vitro assays than clinical studies.
2. Clinical studies of equivalence in the most sensitive indication can 
provide the basis for extrapolation. Therefore data for the usage 
of biosimilars in IBD can be extrapolated from another sensitive 
indication.
3. When a biosimilar product is registered in the EU, it is considered 
to be as efficacious as the reference product when used in accord-
ance with the information provided in the Summary of Product 
Characteristics.
4. Demonstration of safety of biosimilars requires large observa-
tional studies with long-term follow-up in IBD patients. This 
should be supplemented by registries supported by all involved 
stakeholders [manufacturer, healthcare professionals and patients’ 
associations].
5. Adverse events and loss of response due to immunogenicity to a 
biologic drug cannot be expected to be overcome with a biosimilar 
of the same molecule.
6. As for all biologics, traceability should be based on a robust phar-
macovigilance system and the manufacturing risk management 
plan.
7. Switching from the originator to a biosimilar in patients with IBD 
is acceptable. Studies of switching can provide valuable evidence 
for safety and efficacy. Scientific and clinical evidence is lacking 
regarding reverse switching, multiple switching, and cross-switch-
ing among biosimilars in IBD patients
8. Switching from originator to a biosimilar should be per-
formed following appropriate discussion between physicians, 
nurses, pharmacists, and patients, and according to national 
recommendation. The IBD nurse can play a key role in com-
municating the importance and equivalence of biosimilar 
therapy.
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7. Practical Aspects: Communication with the 
Patient
Making treatment decisions in IBD is becoming more complex due 
to the advent of biologic and now biosimilar therapies and shifts in 
the paradigm of care.55 Communicating the need for and risk of ther-
apies to patients has always been challenging, and now healthcare 
professionals need to provide balanced information to assist patients 
to make preference-sensitive decisions.56 Healthcare professionals 
have the responsibility to ensure that all information is given to the 
patient to promote shared decision making, confirming informed 
consent to treatment and evidence-based patient choice.57,58 The 
patient’s health literacy must be considered to ensure that the infor-
mation communicated is at the correct level of understanding59 and 
the benefits and risk outlined.60,61 Patients will require the same level 
of information whether starting on a biologic or a biosimilar.
The decision to initiate a biologic, biosimilar, or non-medical 
biosimilar switch, should always take into account patient prefer-
ence. The information offered must be transparent and the require-
ment of a non-medical switch must be made clear to the patient e.g. 
financial savings or additional services attached to the switch, i.e. 
the ‘biologicals experience’.62 Based on the recent web survey by the 
European Federation of Crohn’s and Ulcerative Colitis Associations 
[EFCCA],63 out of 1181 patients who responded, only 38% had 
ever heard of biosimilars. The respondents worried about biosimi-
lars’ safety profile [47.0%], efficacy [40.3%], and molecular basis 
[35.0%]. Only 25.2% of the respondents had no concerns about 
biosimilars. Just over half [55.9%] of respondents thought that the 
lower cost of the biosimilars should not come before their safety and 
efficacy. Only 12.5% of respondents felt that extrapolation made 
sense. The survey showed that 39.9% felt that patients should be 
systematically informed, and 26.7% felt that patient associations 
should be informed and able to give their opinions. It also revealed 
that 20.9% of the respondents would be against the idea of inter-
changeability, unless the patient was well informed and shared the 
decision. Only 31.0% of the respondents would be fully confident 
about biosimilars, even if they were prescribed and explained by the 
treating physician.63 In order to inform patients on the safety and 
efficacy of biosimilars exhaustively, the communication style must be 
tailored to meet the patients’ needs. In many countries, the IBD nurse 
may be in a central position to support the patient during the initia-
tion of a biosimilar or a switch. The patient’s willingness to com-
mence a medication is influenced by how they judge the need for the 
treatment relative to their concerns about taking it,64 and the rela-
tionship between the patient and IBD nurse is built to develop and 
support these judgements.65 The challenge for the IBD nurse or any 
healthcare professional in this position is to communicate the tan-
gible benefits of the biosimilar product, and in the case of a switch, 
over and above the originator, and this is achieved by the education 
of all concerned in the evidence base for biosimilars. The consulta-
tion must be patient-centred, balanced, and must include the impact 
that the medication will have on the patient’s quality of life.66,67
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